Business
Osteopore Limited (ASX:OSX) Elevates Partnership with Kelyniam for the U.S. Craniofacial Market
Osteopore Limited (ASX:OSX) Elevates Partnership with Kelyniam for the U.S. Craniofacial Market.
About this update from Kelyniam Global, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Osteopore Limited (ASX:OSX) Elevates Partnership with Kelyniam for the U.S. Craniofacial Market\r\n \r\n \r\n\r\n\r\nOsteopore Limited (ASX:OSX) Elevates Partnership with Kelyniam for the U.S. Craniofacial Market\r\n\r\n\r\n\r\n\r\n\r\nPerth, Australia, May 12, 2025 - (ABN Newswire) - Australian-Singaporean regenerative medicine company Osteopore Limited (ASX:OSX) - a global leader in 3D-printed biomimetic and bioresorbable implants - is pleased to announce that the Company has secured a non-exclusive 3-year distribution arrangement with Kelyniam Global, Inc (Kelyniam), a publicly traded medical device company (OBB:KLYG), to market its craniofacial implants in the U.S. \r\nHighlights \r\n- Osteopore strikes non-exclusive 3-year distribution agreement with Kelyniam Global, Inc. (Kelyniam) for its craniofacial implants in the U.S. \r\n- Kelyniam is a publicly traded (OBB:KLYG) medical device company specialising in custom cranial and craniofacial implants that showed strong profitability in 2024. \r\n- Osteopore expects the first purchase to follow promptly after the agreement is signed. \r\nKelyniam is an innovative medical device manufacturing company that specialises in the production of custom cranial and craniofacial PEEK implants. As an industry leader, Kelyniam is the only cranial and craniofacial implant company with a patented integrated fixation system, and that can produce an implant within 24-48 hours for rush and expedited cases. \r\nKelyniam processes are supported by 3D printing, along with advanced design software and CAD/CAM manufacturing capabilities to ensure the highest level of precision is achieved. \r\nKelyniam is poised for growth and announced record revenue in 2024, with revenues increasing 24.6% year-on-year from US$2.7M in 2023 to US$3.3M in 2024, while net operating income was US$277k in 2024 compared to a net operating income loss of US$239k in 2023. \r\nThis augmented partnership with Kelyniam is expected to result in stronger U.S. customer service and support, along with higher precision in securing product listing in hospitals and exposure to industry leading surgeons, both of which are key elements in the product adoption process. Previously, Kelyniam was appointed as a sub-distributor under Bioplate Inc. \r\nWith an addressable market of US$1.1 billion (Compound Annual Growth R...